Loading…

The biology of VSIG4: Implications for the treatment of immune-mediated inflammatory diseases and cancer

V-set and immunoglobulin domain containing 4 (VSIG4), a type I transmembrane receptor exclusively expressed in a subset of tissue-resident macrophages, plays a pivotal role in clearing C3-opsonized pathogens and their byproducts from the circulation. VSIG4 maintains immune homeostasis by suppressing...

Full description

Saved in:
Bibliographic Details
Published in:Cancer letters 2023-01, Vol.553, p.215996-215996, Article 215996
Main Authors: Liu, Bei, Cheng, Li, Gao, Honghao, Zhang, Jiale, Dong, Yanxin, Gao, Wenda, Yuan, Shunzong, Gong, Taiqian, Huang, Wenrong
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c390t-37b203dc564a6f0ef1802eb9c8e5a60d8497047b1b3cd1af8c99a7fea2d8a8cc3
cites cdi_FETCH-LOGICAL-c390t-37b203dc564a6f0ef1802eb9c8e5a60d8497047b1b3cd1af8c99a7fea2d8a8cc3
container_end_page 215996
container_issue
container_start_page 215996
container_title Cancer letters
container_volume 553
creator Liu, Bei
Cheng, Li
Gao, Honghao
Zhang, Jiale
Dong, Yanxin
Gao, Wenda
Yuan, Shunzong
Gong, Taiqian
Huang, Wenrong
description V-set and immunoglobulin domain containing 4 (VSIG4), a type I transmembrane receptor exclusively expressed in a subset of tissue-resident macrophages, plays a pivotal role in clearing C3-opsonized pathogens and their byproducts from the circulation. VSIG4 maintains immune homeostasis by suppressing the activation of complement pathways or T cells and inducing regulatory T-cell differentiation, thereby inhibiting the development of immune-mediated inflammatory diseases but enhancing cancer progression. Consequently, VSIG4 exhibits a potential therapeutic effect for immune-mediated inflammatory diseases, but also is regarded as a novel target of immune checkpoint inhibition in cancer therapy. Recently, soluble VSIG4, the extracellular domain of VSIG4, shed from the surface of macrophages, has been found to be a biomarker to define macrophage activation-related diseases. This review mainly summarizes recent new findings of VSIG4 in macrophage phagocytosis and immune homeostasis, and discusses its potential diagnostic and therapeutic usage in infection, inflammation, and cancer. •Expression of VSIG4 and potential regulatory mechanisms in macrophages.•Role of VSIG4 in regulating macrophage phagocytosis.•Role of VSIG4 in complement pathway and T cell activation.•Role of VSIG4 in tumor microenvironment.•sVSIG4 in diseases related to macrophage activation and beyond.
doi_str_mv 10.1016/j.canlet.2022.215996
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2734167514</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0304383522004839</els_id><sourcerecordid>2734167514</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-37b203dc564a6f0ef1802eb9c8e5a60d8497047b1b3cd1af8c99a7fea2d8a8cc3</originalsourceid><addsrcrecordid>eNp9kU9v1DAUxC1ERZeFb4CQJS5csvW_xDYHJFRBWakSh7ZcLcd-oV4l8WI7SPvt8SqFAwdO7_KbeaMZhN5QsqOEdleHnbPzCGXHCGM7Rlutu2doQ5VkjdSKPEcbwolouOLtJXqZ84EQ0grZvkCXvOOCSyU36PH-EXAf4hh_nHAc8Pe7_Y34gPfTcQzOlhDnjIeYcKlYSWDLBHM5g2GalhmaCXywBTwO8zDaabIlphP2IYPNkLGdPa4xHaRX6GKwY4bXT3eLHr58vr_-2tx-u9lff7ptHNekNFz2jHDv2k7YbiAwUEUY9NopaG1HvBJaEiF72nPnqR2U09rKASzzyirn-Ba9X32PKf5cIBczhexgHO0MccmGSS5oJ1sqKvruH_QQlzTXdGdKC6pZzbJFYqVcijknGMwxhcmmk6HEnJcwB7MuYc5LmHWJKnv7ZL70taS_oj_VV-DjCkBt41eAZLILUKvyIYErxsfw_w-_AV6Ym90</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2739419220</pqid></control><display><type>article</type><title>The biology of VSIG4: Implications for the treatment of immune-mediated inflammatory diseases and cancer</title><source>ScienceDirect Journals</source><creator>Liu, Bei ; Cheng, Li ; Gao, Honghao ; Zhang, Jiale ; Dong, Yanxin ; Gao, Wenda ; Yuan, Shunzong ; Gong, Taiqian ; Huang, Wenrong</creator><creatorcontrib>Liu, Bei ; Cheng, Li ; Gao, Honghao ; Zhang, Jiale ; Dong, Yanxin ; Gao, Wenda ; Yuan, Shunzong ; Gong, Taiqian ; Huang, Wenrong</creatorcontrib><description>V-set and immunoglobulin domain containing 4 (VSIG4), a type I transmembrane receptor exclusively expressed in a subset of tissue-resident macrophages, plays a pivotal role in clearing C3-opsonized pathogens and their byproducts from the circulation. VSIG4 maintains immune homeostasis by suppressing the activation of complement pathways or T cells and inducing regulatory T-cell differentiation, thereby inhibiting the development of immune-mediated inflammatory diseases but enhancing cancer progression. Consequently, VSIG4 exhibits a potential therapeutic effect for immune-mediated inflammatory diseases, but also is regarded as a novel target of immune checkpoint inhibition in cancer therapy. Recently, soluble VSIG4, the extracellular domain of VSIG4, shed from the surface of macrophages, has been found to be a biomarker to define macrophage activation-related diseases. This review mainly summarizes recent new findings of VSIG4 in macrophage phagocytosis and immune homeostasis, and discusses its potential diagnostic and therapeutic usage in infection, inflammation, and cancer. •Expression of VSIG4 and potential regulatory mechanisms in macrophages.•Role of VSIG4 in regulating macrophage phagocytosis.•Role of VSIG4 in complement pathway and T cell activation.•Role of VSIG4 in tumor microenvironment.•sVSIG4 in diseases related to macrophage activation and beyond.</description><identifier>ISSN: 0304-3835</identifier><identifier>EISSN: 1872-7980</identifier><identifier>DOI: 10.1016/j.canlet.2022.215996</identifier><identifier>PMID: 36343787</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>Ablation ; Amino acids ; Animals ; Bacteria ; Biology ; Biomarkers ; Body fat ; By products ; Cancer ; Cell activation ; Cell differentiation ; Complement activation ; Complement component C3 ; Gram-positive bacteria ; Growth factors ; Hemophagocytic lymphohistiocytosis ; Homeostasis ; Humans ; Immune checkpoint ; Immune checkpoint inhibitors ; Immunoglobulins ; Inflammatory diseases ; Kinases ; Liver ; Lymphocytes T ; Macrophage activation syndrome ; Macrophages ; Mice ; Mice, Inbred C57BL ; Mice, Knockout ; Neoplasms - therapy ; Opsonization ; Pathogens ; Phagocytosis ; Proteins ; Receptors, Complement - metabolism ; Tumor necrosis factor-TNF ; Tumor-associated macrophages ; VSIG4</subject><ispartof>Cancer letters, 2023-01, Vol.553, p.215996-215996, Article 215996</ispartof><rights>2022 Elsevier B.V.</rights><rights>Copyright © 2022 Elsevier B.V. All rights reserved.</rights><rights>2022. Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-37b203dc564a6f0ef1802eb9c8e5a60d8497047b1b3cd1af8c99a7fea2d8a8cc3</citedby><cites>FETCH-LOGICAL-c390t-37b203dc564a6f0ef1802eb9c8e5a60d8497047b1b3cd1af8c99a7fea2d8a8cc3</cites><orcidid>0000-0002-8981-0397</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36343787$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, Bei</creatorcontrib><creatorcontrib>Cheng, Li</creatorcontrib><creatorcontrib>Gao, Honghao</creatorcontrib><creatorcontrib>Zhang, Jiale</creatorcontrib><creatorcontrib>Dong, Yanxin</creatorcontrib><creatorcontrib>Gao, Wenda</creatorcontrib><creatorcontrib>Yuan, Shunzong</creatorcontrib><creatorcontrib>Gong, Taiqian</creatorcontrib><creatorcontrib>Huang, Wenrong</creatorcontrib><title>The biology of VSIG4: Implications for the treatment of immune-mediated inflammatory diseases and cancer</title><title>Cancer letters</title><addtitle>Cancer Lett</addtitle><description>V-set and immunoglobulin domain containing 4 (VSIG4), a type I transmembrane receptor exclusively expressed in a subset of tissue-resident macrophages, plays a pivotal role in clearing C3-opsonized pathogens and their byproducts from the circulation. VSIG4 maintains immune homeostasis by suppressing the activation of complement pathways or T cells and inducing regulatory T-cell differentiation, thereby inhibiting the development of immune-mediated inflammatory diseases but enhancing cancer progression. Consequently, VSIG4 exhibits a potential therapeutic effect for immune-mediated inflammatory diseases, but also is regarded as a novel target of immune checkpoint inhibition in cancer therapy. Recently, soluble VSIG4, the extracellular domain of VSIG4, shed from the surface of macrophages, has been found to be a biomarker to define macrophage activation-related diseases. This review mainly summarizes recent new findings of VSIG4 in macrophage phagocytosis and immune homeostasis, and discusses its potential diagnostic and therapeutic usage in infection, inflammation, and cancer. •Expression of VSIG4 and potential regulatory mechanisms in macrophages.•Role of VSIG4 in regulating macrophage phagocytosis.•Role of VSIG4 in complement pathway and T cell activation.•Role of VSIG4 in tumor microenvironment.•sVSIG4 in diseases related to macrophage activation and beyond.</description><subject>Ablation</subject><subject>Amino acids</subject><subject>Animals</subject><subject>Bacteria</subject><subject>Biology</subject><subject>Biomarkers</subject><subject>Body fat</subject><subject>By products</subject><subject>Cancer</subject><subject>Cell activation</subject><subject>Cell differentiation</subject><subject>Complement activation</subject><subject>Complement component C3</subject><subject>Gram-positive bacteria</subject><subject>Growth factors</subject><subject>Hemophagocytic lymphohistiocytosis</subject><subject>Homeostasis</subject><subject>Humans</subject><subject>Immune checkpoint</subject><subject>Immune checkpoint inhibitors</subject><subject>Immunoglobulins</subject><subject>Inflammatory diseases</subject><subject>Kinases</subject><subject>Liver</subject><subject>Lymphocytes T</subject><subject>Macrophage activation syndrome</subject><subject>Macrophages</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Mice, Knockout</subject><subject>Neoplasms - therapy</subject><subject>Opsonization</subject><subject>Pathogens</subject><subject>Phagocytosis</subject><subject>Proteins</subject><subject>Receptors, Complement - metabolism</subject><subject>Tumor necrosis factor-TNF</subject><subject>Tumor-associated macrophages</subject><subject>VSIG4</subject><issn>0304-3835</issn><issn>1872-7980</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kU9v1DAUxC1ERZeFb4CQJS5csvW_xDYHJFRBWakSh7ZcLcd-oV4l8WI7SPvt8SqFAwdO7_KbeaMZhN5QsqOEdleHnbPzCGXHCGM7Rlutu2doQ5VkjdSKPEcbwolouOLtJXqZ84EQ0grZvkCXvOOCSyU36PH-EXAf4hh_nHAc8Pe7_Y34gPfTcQzOlhDnjIeYcKlYSWDLBHM5g2GalhmaCXywBTwO8zDaabIlphP2IYPNkLGdPa4xHaRX6GKwY4bXT3eLHr58vr_-2tx-u9lff7ptHNekNFz2jHDv2k7YbiAwUEUY9NopaG1HvBJaEiF72nPnqR2U09rKASzzyirn-Ba9X32PKf5cIBczhexgHO0MccmGSS5oJ1sqKvruH_QQlzTXdGdKC6pZzbJFYqVcijknGMwxhcmmk6HEnJcwB7MuYc5LmHWJKnv7ZL70taS_oj_VV-DjCkBt41eAZLILUKvyIYErxsfw_w-_AV6Ym90</recordid><startdate>20230128</startdate><enddate>20230128</enddate><creator>Liu, Bei</creator><creator>Cheng, Li</creator><creator>Gao, Honghao</creator><creator>Zhang, Jiale</creator><creator>Dong, Yanxin</creator><creator>Gao, Wenda</creator><creator>Yuan, Shunzong</creator><creator>Gong, Taiqian</creator><creator>Huang, Wenrong</creator><general>Elsevier B.V</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8981-0397</orcidid></search><sort><creationdate>20230128</creationdate><title>The biology of VSIG4: Implications for the treatment of immune-mediated inflammatory diseases and cancer</title><author>Liu, Bei ; Cheng, Li ; Gao, Honghao ; Zhang, Jiale ; Dong, Yanxin ; Gao, Wenda ; Yuan, Shunzong ; Gong, Taiqian ; Huang, Wenrong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-37b203dc564a6f0ef1802eb9c8e5a60d8497047b1b3cd1af8c99a7fea2d8a8cc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Ablation</topic><topic>Amino acids</topic><topic>Animals</topic><topic>Bacteria</topic><topic>Biology</topic><topic>Biomarkers</topic><topic>Body fat</topic><topic>By products</topic><topic>Cancer</topic><topic>Cell activation</topic><topic>Cell differentiation</topic><topic>Complement activation</topic><topic>Complement component C3</topic><topic>Gram-positive bacteria</topic><topic>Growth factors</topic><topic>Hemophagocytic lymphohistiocytosis</topic><topic>Homeostasis</topic><topic>Humans</topic><topic>Immune checkpoint</topic><topic>Immune checkpoint inhibitors</topic><topic>Immunoglobulins</topic><topic>Inflammatory diseases</topic><topic>Kinases</topic><topic>Liver</topic><topic>Lymphocytes T</topic><topic>Macrophage activation syndrome</topic><topic>Macrophages</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Mice, Knockout</topic><topic>Neoplasms - therapy</topic><topic>Opsonization</topic><topic>Pathogens</topic><topic>Phagocytosis</topic><topic>Proteins</topic><topic>Receptors, Complement - metabolism</topic><topic>Tumor necrosis factor-TNF</topic><topic>Tumor-associated macrophages</topic><topic>VSIG4</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Bei</creatorcontrib><creatorcontrib>Cheng, Li</creatorcontrib><creatorcontrib>Gao, Honghao</creatorcontrib><creatorcontrib>Zhang, Jiale</creatorcontrib><creatorcontrib>Dong, Yanxin</creatorcontrib><creatorcontrib>Gao, Wenda</creatorcontrib><creatorcontrib>Yuan, Shunzong</creatorcontrib><creatorcontrib>Gong, Taiqian</creatorcontrib><creatorcontrib>Huang, Wenrong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Bei</au><au>Cheng, Li</au><au>Gao, Honghao</au><au>Zhang, Jiale</au><au>Dong, Yanxin</au><au>Gao, Wenda</au><au>Yuan, Shunzong</au><au>Gong, Taiqian</au><au>Huang, Wenrong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The biology of VSIG4: Implications for the treatment of immune-mediated inflammatory diseases and cancer</atitle><jtitle>Cancer letters</jtitle><addtitle>Cancer Lett</addtitle><date>2023-01-28</date><risdate>2023</risdate><volume>553</volume><spage>215996</spage><epage>215996</epage><pages>215996-215996</pages><artnum>215996</artnum><issn>0304-3835</issn><eissn>1872-7980</eissn><abstract>V-set and immunoglobulin domain containing 4 (VSIG4), a type I transmembrane receptor exclusively expressed in a subset of tissue-resident macrophages, plays a pivotal role in clearing C3-opsonized pathogens and their byproducts from the circulation. VSIG4 maintains immune homeostasis by suppressing the activation of complement pathways or T cells and inducing regulatory T-cell differentiation, thereby inhibiting the development of immune-mediated inflammatory diseases but enhancing cancer progression. Consequently, VSIG4 exhibits a potential therapeutic effect for immune-mediated inflammatory diseases, but also is regarded as a novel target of immune checkpoint inhibition in cancer therapy. Recently, soluble VSIG4, the extracellular domain of VSIG4, shed from the surface of macrophages, has been found to be a biomarker to define macrophage activation-related diseases. This review mainly summarizes recent new findings of VSIG4 in macrophage phagocytosis and immune homeostasis, and discusses its potential diagnostic and therapeutic usage in infection, inflammation, and cancer. •Expression of VSIG4 and potential regulatory mechanisms in macrophages.•Role of VSIG4 in regulating macrophage phagocytosis.•Role of VSIG4 in complement pathway and T cell activation.•Role of VSIG4 in tumor microenvironment.•sVSIG4 in diseases related to macrophage activation and beyond.</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>36343787</pmid><doi>10.1016/j.canlet.2022.215996</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-8981-0397</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0304-3835
ispartof Cancer letters, 2023-01, Vol.553, p.215996-215996, Article 215996
issn 0304-3835
1872-7980
language eng
recordid cdi_proquest_miscellaneous_2734167514
source ScienceDirect Journals
subjects Ablation
Amino acids
Animals
Bacteria
Biology
Biomarkers
Body fat
By products
Cancer
Cell activation
Cell differentiation
Complement activation
Complement component C3
Gram-positive bacteria
Growth factors
Hemophagocytic lymphohistiocytosis
Homeostasis
Humans
Immune checkpoint
Immune checkpoint inhibitors
Immunoglobulins
Inflammatory diseases
Kinases
Liver
Lymphocytes T
Macrophage activation syndrome
Macrophages
Mice
Mice, Inbred C57BL
Mice, Knockout
Neoplasms - therapy
Opsonization
Pathogens
Phagocytosis
Proteins
Receptors, Complement - metabolism
Tumor necrosis factor-TNF
Tumor-associated macrophages
VSIG4
title The biology of VSIG4: Implications for the treatment of immune-mediated inflammatory diseases and cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T19%3A13%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20biology%20of%20VSIG4:%20Implications%20for%20the%20treatment%20of%20immune-mediated%20inflammatory%20diseases%20and%20cancer&rft.jtitle=Cancer%20letters&rft.au=Liu,%20Bei&rft.date=2023-01-28&rft.volume=553&rft.spage=215996&rft.epage=215996&rft.pages=215996-215996&rft.artnum=215996&rft.issn=0304-3835&rft.eissn=1872-7980&rft_id=info:doi/10.1016/j.canlet.2022.215996&rft_dat=%3Cproquest_cross%3E2734167514%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c390t-37b203dc564a6f0ef1802eb9c8e5a60d8497047b1b3cd1af8c99a7fea2d8a8cc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2739419220&rft_id=info:pmid/36343787&rfr_iscdi=true